Development of NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor

By Kimura Shinya   Niwa Tomoko   Hirabayashi Kazuko   Maekawa Taira  

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 7, 2006-11 ,pp. : 55-61

Springer Publishing Company

Access to resources Recommend Favorite

Development of NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor

By Kimura Shinya   Niwa Tomoko   Hirabayashi Kazuko   Maekawa Taira  

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 1, 2006-11 ,pp. : 55-61

Springer Publishing Company

Access to resources Recommend Favorite

Switching to second‐generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib‐treated patients with chronic myeloid leukemia with more than 10% of BCR‐ABL/ABL ratio at 3 months

By  

Cancer Medicine, Vol. 4, Iss. 7, 2015-07 ,pp. : 995-1002

John Wiley & Sons Inc

Access to resources Recommend Favorite

Plant-Derived Protein Tyrosine Kinase Inhibitors as Anticancer Agents

By  

Current Medicinal Chemistry - Anti-Cancer Agents, Vol. 4, Iss. 2, 2004-03 ,pp. : 173-197

Bentham Science Publishers

Access to resources Recommend Favorite

Focal adhesion kinase regulates the phosphorylation protein tyrosine phosphatase-α at Tyr789 in breast cancer cells

By                  

Molecular Medicine Reports, Vol. 11, Iss. 6, 2015-01 ,pp. : 4303-4308

Spandidos Publications

Access to resources Recommend Favorite